EXPLORE THE UNIVERSITY OF OXFORD'S WORLD-CLASS RESEARCH

1 entry found
1
Conference item icon
Conference item

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors

  • Pacey, S, Blackhall, F, Garcia-Corbacho, J, et al.
  • 2016-10-01
File available icon
Peer reviewed icon
Link to publisher copy available icon
FILTER RESULTS

TO TOP